Immuneering Corporation (NASDAQ: IMRX) began the last session of the week on the upside. The New York-based company, a late-stage clinical oncology concern focused on keeping cancer patients alive and helping them thrive, today reported financial results for the first quarter ended March 31, 2026.
The company ended Q1 2026 with $198.6 million in cash, cash equivalents and marketable securities with anticipated runway into 2029.
"We are excited that new survival data from 55 first-line pancreatic cancer patients treated with atebimetinib + mGnP in our Phase 2a clinical trial will be reported in an oral presentation at the ASCO Annual Meeting on June 1,” said CEO Ben Zeskind.
“We believe the upcoming presentation at ASCO is an excellent opportunity to build on the recent momentum in second-line pancreatic cancer and demonstrate atebimetinib’s potential to provide a differentiated first-line option for patients. Our Phase 3 study of atebimetinib + mGnP in first-line pancreatic cancer patients, MAPKeeper 301, is now recruiting patients, and we remain on track to dose the first patient by mid-2026. Our Phase 2 lung cancer trial is on track to dose the first patient in the second half of the year.
“I believe we are entering a new era in cancer care where treatments have the potential to drive longer survival with fewer harsh side effects, and that atebimetinib will play an important role in that future."
IMRX shares acquired 11 cents, or 2.1%, to $5.25.
Related Stories
